Exonuclease 1 (EXO1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Lung Adenocarcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385. doi:10.3322/caac.21565
   PubMed Web of Science ®Google Scholar
• Patel MI, Cheng I, Gomez SL. US lung cancer trends by histologic type. Cancer. 2015;121(7):1150–1152. doi:10.1002/cncr.29180
   PubMed Web of Science ®Google Scholar
• Kim YH, Nagai H, Ozasa H, et al. Therapeutic strategy for non-small-cell lung cancer patients with brain metastases (Review). Biomed Rep. 2013;1(5):691–696. doi:10.3892/br.2013.151
   PubMedGoogle Scholar
• Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019;16(6):341–355. doi:10.1038/s41571-019-0173-9
   PubMed Web of Science ®Google Scholar
• Moya-Horno I, Viteri S, Karachaliou N, et al. Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Ther Adv Med Oncol. 2018;10:10. doi:10.1177/1758834017745012
   Web of Science ®Google Scholar
• Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52:103–109. doi:10.1016/j.semcancer.2017.11.019
   PubMed Web of Science ®Google Scholar
• Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung Cancer. N Engl J Med. 2018;378(21):1976–1986. doi:10.1056/NEJMoa1716078
   PubMed Web of Science ®Google Scholar
• Pikor LA, Ramnarine VR, Lam S, et al. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013;82(2):179–189. doi:10.1016/j.lungcan.2013.07.025
   PubMed Web of Science ®Google Scholar
• Keijzers G, Liu D, Rasmussen LJ. Exonuclease 1 and its versatile roles in DNA repair. Crit Rev Biochem Mol Biol. 2016;51(6):440–451. doi:10.1080/10409238.2016.1215407
   PubMed Web of Science ®Google Scholar
• Keijzers G, Bakula D, Petr MA, et al. Human exonuclease 1 (EXO1) regulatory functions in DNA replication with putative roles in cancer. Int J Mol Sci. 2018;20(1):20. doi:10.3390/ijms20010074
   PubMed Web of Science ®Google Scholar
• Xue Y, Marvin ME, Ivanova IG, et al. Rif1 and Exo1 regulate the genomic instability following telomere losses. Aging Cell. 2016;15(3):553–562. doi:10.1111/acel.12466
   PubMed Web of Science ®Google Scholar
• Goellner EM, Putnam CD, Kolodner RD. Exonuclease 1-dependent and independent mismatch repair. DNA Repair (Amst). 2015;32:24–32. doi:10.1016/j.dnarep.2015.04.010
   PubMed Web of Science ®Google Scholar
• Goellner EM, Putnam CD, Graham WJ, et al. Identification of Exo1-Msh2 interaction motifs in DNA mismatch repair and new Msh2-binding partners. Nat Struct Mol Biol. 2018;25(8):650. doi:10.1038/s41594-018-0092-y
   PubMed Web of Science ®Google Scholar
• Goellner EM, Smith CE, Campbell CS, et al. PCNA and Msh2-Msh6 activate an mlh1-pms1 endonuclease pathway required for Exo1-independent mismatch repair. Mol Cell. 2014;55(2):291–304. doi:10.1016/j.molcel.2014.04.034
   PubMed Web of Science ®Google Scholar
• Dai Y, Tang Z, Yang Z, et al. EXO1 overexpression is associated with poor prognosis of hepatocellular carcinoma patients. Cell Cycle. 2018;17(19–20):2386–2397. doi:10.1080/15384101.2018.1534511
   PubMed Web of Science ®Google Scholar
• Luo F, Wang Y-Z, Lin D, et al. Exonuclease 1 expression is associated with clinical progression, metastasis, and survival prognosis of prostate cancer. J Cell Biochem. 2019;120(7):11383–11389. doi:10.1002/jcb.28415
   PubMed Web of Science ®Google Scholar
• Qi L, Zhou B, Chen J, et al. Significant prognostic values of differentially expressed-aberrantly methylated hub genes in breast cancer. J Cancer. 2019;10(26):6618–6634. doi:10.7150/jca.33433
   PubMed Web of Science ®Google Scholar
• Chen J, Wang Z, Shen X, et al. Identification of novel biomarkers and small molecule drugs in human colorectal cancer by microarray and bioinformatics analysis. Mol Genet Genomic Med. 2019;7(7). doi:10.1002/mgg3.713.
   Web of Science ®Google Scholar
• Jin G, Wang H, Hu Z, et al. Potentially functional polymorphisms of EXO1 and risk of lung cancer in a Chinese population: a case-control analysis. Lung Cancer. 2008;60(3):340–346. doi:10.1016/j.lungcan.2007.11.003
   PubMed Web of Science ®Google Scholar
• Hsu N-Y, Wang H-C, Wang C-H, et al. Lung cancer susceptibility and genetic polymorphisms of Exo1 gene in Taiwan. Anticancer Res. 2009;29(2):725–730.
   PubMed Web of Science ®Google Scholar
• Matakidou A, El Galta R, Webb EL, et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet. 2007;16(19):2333–2340. doi:10.1093/hmg/ddm190
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–404. doi:10.1158/2159-8290.CD-12-0095
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1–6. doi:10.1016/S1476-5586(04)80047-2
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–w102. doi:10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e10. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable A, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D13. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Stelzer G, Rosen N, Plaschkes I, et al. The geneCards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics. 2016;54(1):1.30.1–1.3. doi:10.1002/cpbi.5
   PubMedGoogle Scholar
• Azim HA, Peccatori FA, Brohée S, et al. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res. 2015;17(1):24. doi:10.1186/s13058-015-0538-7
   PubMed Web of Science ®Google Scholar
• Meador CB, Hata AN. Acquired resistance to targeted therapies in NSCLC: updates and evolving insights. Pharmacol Ther. 2020;210.
   Web of Science ®Google Scholar
• de Sousa JF, Serafim RB, de Freitas LM, et al. DNA repair genes in astrocytoma tumorigenesis, progression and therapy resistance. Genet Mol Biol. 2020;43.
   Web of Science ®Google Scholar
• Sun J, Wang C, Zhang Y, et al. Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases. Nat Commun. 2019;10(1):3190. doi:10.1038/s41467-019-10987-3
   PubMedGoogle Scholar
• Tomimatsu N, Mukherjee B, Harris JL, et al. DNA-damage-induced degradation of EXO1 exonuclease limits DNA end resection to ensure accurate DNA repair. J Biol Chem. 2017;292(26):10779–10790. doi:10.1074/jbc.M116.772475
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhao D, Yan C, et al. Associations between nine polymorphisms in EXO1 and cancer susceptibility: a systematic review and meta-analysis of 39 case-control studies. Sci Rep. 2016;6.
   PubMedGoogle Scholar
• Li Z, Sang M, Tian Z, et al. Identification of key biomarkers and potential molecular mechanisms in lung cancer by bioinformatics analysis. Oncol Lett. 2019;18(5):4429–4440. doi:10.3892/ol.2019.10796
   PubMed Web of Science ®Google Scholar
• Gao Y, Hayes RB, Huang W-Y, et al. DNA repair gene polymorphisms and tobacco smoking in the risk for colorectal adenomas. Carcinogenesis. 2011;32(6):882–887. doi:10.1093/carcin/bgr071
   PubMed Web of Science ®Google Scholar
• de Sousa JF, Torrieri R, Serafim RB, et al. Expression signatures of DNA repair genes correlate with survival prognosis of astrocytoma patients. Tumour Biol. 2017;39(4):1010428317694552. doi:10.1177/1010428317694552
   Google Scholar
• Liberti S, Andersen S, Wang J, et al. Bi-directional routing of DNA mismatch repair protein human exonuclease 1 to replication foci and DNA double strand breaks. DNA Repair. 2011;10(1):73–86. doi:10.1016/j.dnarep.2010.09.023
   PubMed Web of Science ®Google Scholar
• Chen X, Paudyal S, Chin R, et al. PCNA promotes processive DNA end resection by Exo1. Nucleic Acids Res. 2013;41(20):9325–9338. doi:10.1093/nar/gkt672
   PubMed Web of Science ®Google Scholar
• Viktorsson K, De Petris L, Lewensohn RJB, et al. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun. 2005;331(3):868–880. doi:10.1016/j.bbrc.2005.03.192
   PubMed Web of Science ®Google Scholar
• Liu H, Liu Y, Yang F, et al. Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer. Nucleic Acids Res. 2020;48(7):3638–3656. doi:10.1093/nar/gkaa130
   PubMed Web of Science ®Google Scholar
• He D, Li T, Sheng M, et al. Exonuclease 1 (Exo1) participates in mammalian non-homologous end joining and contributes to drug resistance in ovarian cancer. Med Sci Monit. 2020;26.
   Web of Science ®Google Scholar
• Li R, Gu J, Heymach JV, et al. Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy. Carcinogenesis. 2017;38(4):419–424. doi:10.1093/carcin/bgx014
   PubMed Web of Science ®Google Scholar
• Sansregret L, Vanhaesebroeck B, Swanton C. Determinants and clinical implications of chromosomal instability in cancer. Nat Rev Clin Oncol. 2018;15(3):139–150. doi:10.1038/nrclinonc.2017.198
   PubMed Web of Science ®Google Scholar
• Liu D, Keijzers G, Rasmussen LJ. DNA mismatch repair and its many roles in eukaryotic cells. Mutat Res Rev Mutat Res. 2017;773:174–187.
   PubMed Web of Science ®Google Scholar
• Varella-Garcia M. Chromosomal and genomic changes in lung cancer. Cell Adh Migr. 2010;4(1):100–106. doi:10.4161/cam.4.1.10884
   PubMed Web of Science ®Google Scholar
• Fu F, Zhang Y, Gao Z, et al. Development and validation of a five-gene model to predict postoperative brain metastasis in operable lung adenocarcinoma. Int J Cancer. 2020;147(2):584–592. doi:10.1002/ijc.32981
   PubMed Web of Science ®Google Scholar
• Amin NS, Nguyen MN, Oh S, et al. Exo1-dependent mutator mutations: model system for studying functional interactions in mismatch repair. Mol Cell Biol. 2001;21(15):5142–5155. doi:10.1128/MCB.21.15.5142-5155.2001
   PubMed Web of Science ®Google Scholar
• Bolderson E, Tomimatsu N, Richard DJ, et al. Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. Nucleic Acids Res. 2010;38(6):1821–1831. doi:10.1093/nar/gkp1164
   PubMed Web of Science ®Google Scholar
• Shenker RF, McTyre ER, Ruiz J, et al. The effects of smoking status and smoking history on patients with brain metastases from lung cancer. Cancer Med. 2017;6(5):944–952. doi:10.1002/cam4.1058
   PubMed Web of Science ®Google Scholar
• Wu SY, Xing F, Sharma S, et al. Nicotine promotes brain metastasis by polarizing microglia and suppressing innate immune function. J Exp Med. 2020;217(8):217. doi:10.1084/jem.20191131
   Web of Science ®Google Scholar
• Tan Q, Wang G, Huang J, et al. Epigenomic analysis of lung adenocarcinoma reveals novel DNA methylation patterns associated with smoking. Onco Targets Ther. 2013;6:1471–1479. doi:10.2147/OTT.S51041
   PubMed Web of Science ®Google Scholar
• Zhou L, Gao HF, Liu DS, et al. Gene expression profiling of brain metastatic cell from triple negative breast cancer: understanding the molecular events. Gene. 2018;640:21–27. doi:10.1016/j.gene.2017.10.019
   PubMed Web of Science ®Google Scholar
• Zeni E, Mazzetti L, Miotto D, et al. Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J. 2007;30(4):627–632. doi:10.1183/09031936.00129306
   PubMed Web of Science ®Google Scholar
• Villanueva MT. Cancer immunotherapy: macrophages steal the show. Nat Rev Drug Discov. 2017;16(7):455. doi:10.1038/nrd.2017.126
   PubMed Web of Science ®Google Scholar
• Donnem T, Hald SM, Paulsen EE, et al. Stromal CD8+T-cell density—A promising supplement to tnm staging in non–small cell lung cancer. Clin Cancer Res. 2015;21(11):2635–2643. doi:10.1158/1078-0432.CCR-14-1905
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gallastegui N, Rosenblatt JD. Regulatory B cells in anti-tumor immunity. Int Immunol. 2015;27(10):521–530. doi:10.1093/intimm/dxv034
   PubMed Web of Science ®Google Scholar
• Saha T, Sundaravinayagam D, Di Virgilio M. Charting a DNA repair roadmap for immunoglobulin class switch recombination. Trends Biochem Sci. 2020. doi:10.1016/j.tibs.2020.10.005
   PubMed Web of Science ®Google Scholar
• Chi X, Li Y, Qiu X. V(D)J recombination, somatic hypermutation and class switch recombination of immunoglobulins: mechanism and regulation. Immunology. 2020;160(3):233–247. doi:10.1111/imm.13176
   PubMed Web of Science ®Google Scholar
• Bouaziz JD, Yanaba K, Venturi GM, et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci U S A. 2007;104(52):20878–20883. doi:10.1073/pnas.0709205105
   PubMed Web of Science ®Google Scholar
• Zhu W, Germain C, Liu Z, et al. A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+T cell receptor repertoire clonality. Oncoimmunology. 2015;4(12):e1051922. doi:10.1080/2162402X.2015.1051922
   PubMed Web of Science ®Google Scholar
• Xu F, Chen JX, Yang XB, et al. Analysis of lung adenocarcinoma subtypes based on immune signatures identifies clinical implications for cancer therapy. Mol Ther Oncolytics. 2020;17:241–249. doi:10.1016/j.omto.2020.03.021
   PubMed Web of Science ®Google Scholar
• Rosenthal R, Cadieux EL, Salgado R, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567(7749):479–485. doi:10.1038/s41586-019-1032-7
   PubMed Web of Science ®Google Scholar
• Germain C, Gnjatic S, Tamzalit F, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med. 2014;189(7):832–844. doi:10.1164/rccm.201309-1611OC
   PubMed Web of Science ®Google Scholar